Non-viral, DNA-based in vivo cell-engineering platform converting adoptive cell therapies into direct in‑patient gene treatments for oncology and autoimmune patients. Simplifies treatment workflow, increases patient accessibility and potential clinical benefit, and enables more cost‑effective manufacturing.